REG - Ilika plc - Initial Stereax M300 Shipments

IlikaAnnouncement

Today 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20251218:nRSR0272Ma&default-theme=true

RNS Number : 0272M  Ilika plc  18 December 2025

18 December 2025

Ilika plc

('Ilika,' the 'Company,' or the 'Group')

 

Ilika Announces Initial Stereax M300 Shipments

 

Commencement of Shipping Marks Important Commercial Milestone

 

Ilika (AIM: IKA), the UK pioneer in solid state battery technology, announces
it has commenced shipping prototype Stereax M300s to customers, meeting an
important commercial milestone.

 

These initial deliveries will be allocated to the 21 customers which form
Ilika's existing order book, many of whom have previously received Stereax
batteries for evaluation from the Company's UK pilot line. A number of
batteries from the initial batches will be allocated to the extensive M300
testing programme, which is designed to generate a larger body of test data
relevant to exciting applications in active implantable medical devices
(AIMDs). Applications include powering implanted sensors, neurostimulators,
orthopaedic implants, orthodontic wearables and ophthalmology devices. With
its small footprint and enhanced charging capabilities, Stereax is ideally
suited to meet the needs of AIMDs, offering benefits that include: reduced
surgery time, the ability to place the implant closer to the point of therapy,
long-lasting performance, user recharging at home and the ability to power
Bluetooth radio. Ilika and its strategic partner, Cirtec Medical Corp, will
solicit feedback from this core customer group to verify customer experience
before ramping production.

 

This milestone progresses the 10-year manufacturing agreement signed in August
2023, in which Cirtec Medical, a leading US medical device manufacturer, will
produce Ilika's Stereax battery portfolio.

 

Daniel Weinstein, Co-Founder and Chief Executive Officer at Lura Health, a
provider of non-invasive health management solutions using continuous salivary
monitoring, said: "As one of the first customers to receive M300 prototypes,
we are excited to be working with Ilika and Cirtec Medical to demonstrate the
deployment of Stereax miniature batteries in our range of non-invasive
microsensors for salivary health markers."

 

Shawn Martin, Vice President at Cirtec Medical, said: "The Stereax product is
an excellent addition to our world-leading capabilities in advanced
miniaturised electronics designed for life-changing medical devices."

 

Graeme Purdy, CEO of Ilika, said: "After successfully transferring Stereax
technology to Cirtec Medical's world-class manufacturing facility in Lowell,
Massachusetts, we are looking forward to intensifying our customer engagement
and servicing their needs for implantable power management devices. The
applications form a market of over $40bn with high single digit CAGR, with the
miniature battery component alone worth over $250m."

 

The information communicated within this announcement is deemed to constitute
inside information as stipulated under the Market Abuse Regulations (EU) No.
596/2014 which is part of UK law by virtue of the European Union (withdrawal)
Act 2018. Upon the publication of this announcement, this inside information
is now considered to be in the public domain.

 

--ENDS--

 

Enquiries:

 

 Ilika Plc                                             www.ilika.com (http://www.ilika.com/)
 Graeme Purdy, Chief Executive

                                                     Via FTI Consulting
 Jason Stewart, Chief Financial Officer

 Cavendish Capital Markets Limited (Nomad and Broker)  +44 (0)131 220 9772
 Peter Lynch

                                                     +44 (0)131 220 9771
 Neil McDonald

 FTI Consulting (Comms Advisors)                       ilika@fticonsulting.com

 Ben Brewerton

 Elizabeth Adams

 Dwight Burden

 

About Ilika plc

 

Ilika is a global expert in the development of solid-state battery technology
for electric vehicles, medical devices and consumer appliances. The Company's
pioneering next-generation technologies aim to provide scalable, affordable
alternatives to conventional batteries, to industries which need to
incorporate a smaller, lighter, and safer power source in their products.

 

The Company has two product lines. Its Stereax batteries are designed for
powering miniature medical implants, industrial wireless sensors and Internet
of Things (IoT) applications and the Goliath large format batteries are
designed for EV cars and cordless appliances.

 

Through its licensing business model, Ilika supplies its IP portfolio to both
OEMs and manufacturing partners in exchange for a license fee and future
royalties.

 

About Cirtec Medical‍

 

Cirtec Medical is a global leader in design, development, and manufacturing of
complex Class II and III medical devices, specializing inactive implant
systems, interventional devices, precision components, and thin film and
microelectronics. Since 1987, Cirtec Medical has built extensive in-house
capabilities that enable the company to serve as a single-source partner and
collaborate with customers to transform their technology into innovative
medical devices across a wide array of therapies, including cardiology,
neurology, orthopedics and other minimally invasive device applications.
Cirtec Medical's deep expertise in precision component design and
manufacturing supports every stage of the product lifecycle, ensuring
uncompromising quality and performance. With 11 global facilities and a
vertically integrated approach, Cirtec Medical aims to expedite time to
market, reduce risk, and accelerate revenue generation for our partners. Learn
more at CirtecMed.com.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCTRBTTMTBBTLA



            Copyright 2019 Regulatory News Service, all rights reserved